Ezgi Pehlivanlar Yavrucu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ezgi Pehlivanlar Yavrucu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Buğra Aksel
Karadeniz Technical University
2 shared publications - Begüm Nurpelin Sağlık
Department of Pharmaceutical Chemistry, Faculty of Pharmacy Anadolu University Eskisehir Türkiye
2 shared publications - Hasan Erdinç Sellitepe
Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
2 shared publications - Hilal Zıvalı
Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
2 shared publications - Rahime Şimşek
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Türkiye
2 shared publications - İnci Selin Doğan
Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 203-208
CytoSorb hemoadsorption in propafenone poisoning: a case report
Background: Propafenone overdose is a rare but potentially fatal condition due to its potent sodium channel-blocking and cardiodepressant effects. Conventional extracorporeal elimination methods are typically ineffective owing to the drug’s high protein-binding affinity and large volume of distribution. Hemoadsorption using the CytoSorb® device, although primarily developed for sepsis, may offer a novel therapeutic option in such intoxications. Case Presentation: We describe a 38-year-old turkish female with a history of panic disorder and paroxysmal atrial fibrillation who presented to the emergency department after a suicide attempt involving the ingestion of an estimated 40 tablets of 150 mg propafenone. She exhibited generalized tonic-clonic seizures, severe metabolic acidosis, hypotension (BP 70/50 mmHg), bradycardia (HR 55 bpm), and QRS prolongation (>150 ms). Despite high-dose intravenous sodium bicarbonate, benzodiazepines, and vasopressor support, the patient’s hemodynamic instability persisted. After ICU admission and further deterioration, the patient was intubated, and PiCCO monitoring was initiated. As a last resort prior to ECMO initiation, CytoSorb® hemoadsorption therapy was commenced. Within one hour, her ECG normalized, vasopressors were rapidly weaned, and cardiac index improved significantly. She was extubated 21 hours later and discharged without sequelae. Conclusions: This case highlights the potential use of CytoSorb® hemoadsorption as an adjunctive therapy in severe propafenone poisoning, particularly in patients exhibiting refractory cardiotoxicity. Hemoadsorption may contribute to rapid clinical recovery and could potentially avert the need for more invasive interventions such as ECMO. Further clinical data are needed to validate its efficacy in this context.
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 203-208
Open AccessCytoSorb hemoadsorption in propafenone poisoning: a case report
Background: Propafenone overdose is a rare but potentially fatal condition due to its potent sodium channel-blocking and cardiodepressant effects. Conventional extracorporeal elimination methods are typically ineffective owing to the drug’s high protein-binding affinity and large volume of distribution. Hemoadsorption using the CytoSorb® device, although primarily developed for sepsis, may offer a novel therapeutic option in such intoxications. Case Presentation: We describe a 38-year-old turkish female with a history of panic disorder and paroxysmal atrial fibrillation who presented to the emergency department after a suicide attempt involving the ingestion of an estimated 40 tablets of 150 mg propafenone. She exhibited generalized tonic-clonic seizures, severe metabolic acidosis, hypotension (BP 70/50 mmHg), bradycardia (HR 55 bpm), and QRS prolongation (>150 ms). Despite high-dose intravenous sodium bicarbonate, benzodiazepines, and vasopressor support, the patient’s hemodynamic instability persisted. After ICU admission and further deterioration, the patient was intubated, and PiCCO monitoring was initiated. As a last resort prior to ECMO initiation, CytoSorb® hemoadsorption therapy was commenced. Within one hour, her ECG normalized, vasopressors were rapidly weaned, and cardiac index improved significantly. She was extubated 21 hours later and discharged without sequelae. Conclusions: This case highlights the potential use of CytoSorb® hemoadsorption as an adjunctive therapy in severe propafenone poisoning, particularly in patients exhibiting refractory cardiotoxicity. Hemoadsorption may contribute to rapid clinical recovery and could potentially avert the need for more invasive interventions such as ECMO. Further clinical data are needed to validate its efficacy in this context.
- 23 August 2026
- Published by Taylor & Francis in Polycyclic Aromatic Compounds
- Vol. 46 (8) , 1441-1470
Difluoromethoxy-Substituted Hexahydroquinolines as Multi-Target Anti-Inflammatory Agents: Mechanistic and Metabolomic Insights
1. Inflammation is a complex biological response that plays a pivotal role in the pathogenesis of numerous human diseases. It is broadly classified into acute and chronic forms. Acute inflammation ...
- 23 August 2026
- Published by Taylor & Francis in Polycyclic Aromatic Compounds
- Vol. 46 (8) , 1441-1470
Difluoromethoxy-Substituted Hexahydroquinolines as Multi-Target Anti-Inflammatory Agents: Mechanistic and Metabolomic Insights
1. Inflammation is a complex biological response that plays a pivotal role in the pathogenesis of numerous human diseases. It is broadly classified into acute and chronic forms. Acute inflammation ...
- Open Access
- 15 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
From Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors
Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.
- 15 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
Open AccessFrom Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors
Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.
- 14 July 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (1) , e70347
Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B
Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.
- 14 July 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (1) , e70347
Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B
Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.
- Open Access
- 20 August 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 48 (4) , 659-675
Synthesis and Characterization of New Hexahydroquinoline Derivatives, Evaluation of Their Cytotoxicity, Intracellular ROS Production and Inhibitory Effects on Inflammatory Mediators
Inflammation is a response to injury and infection in the organism. It can be categorized as acute and chronic inflammation. Chronic inflammation is the underlying cause of many diseases such as Alzheimer's, diabetes, rheumatoid arthritis, atherosclerosis and cardiovascular diseases. Recent studies have proven the anti-inflammatory properties of 1,4-dihydropyridines (1,4-DHPs) and its derivatives, which have many biological properties including calcium channel blockers. The structures of the synthesized compounds were elucidated by IR, 1H-NMR, 13C-NMR and HRMS methods. The cytotoxic properties of the compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method in 3T3 cell line. Among the 15 compounds, the three compounds with the lowest cytotoxic properties were selected for further experiments. Inflammation was induced by lipooxygenase (LPS) and the effects of the selected compounds on the levels of reactive oxygen species (ROS), cytokines, complement C3 and C9 regulatory proteins were investigated. It was found that three selected compounds decreased the transforming growth factor beta 1 (TGF-b1) levels. Among these compounds, compound 3e provided the most significant decrease in this cytokine. Moreover, compound 3e increased both C3 and C9 levels. Molecular modeling studies also showed that compound 3e has a better affinity for TGF-b1. When the binding modes of these compounds in the active site of TGF-b1were analyzed, it was found that compound 3e had hydrophobic interactions with amino acids Leu142, Tyr84, and Ile13; halogen bond interactions with Asp92 and hydrogen bond interactions with amino acids Ser89, Gly88, and Gly14 in the active binding site. Further in vitro and in vivo studies are needed to show the possible mechanism of action of compound 3e.
- 20 August 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 48 (4) , 659-675
Open AccessSynthesis and Characterization of New Hexahydroquinoline Derivatives, Evaluation of Their Cytotoxicity, Intracellular ROS Production and Inhibitory Effects on Inflammatory Mediators
Inflammation is a response to injury and infection in the organism. It can be categorized as acute and chronic inflammation. Chronic inflammation is the underlying cause of many diseases such as Alzheimer's, diabetes, rheumatoid arthritis, atherosclerosis and cardiovascular diseases. Recent studies have proven the anti-inflammatory properties of 1,4-dihydropyridines (1,4-DHPs) and its derivatives, which have many biological properties including calcium channel blockers. The structures of the synthesized compounds were elucidated by IR, 1H-NMR, 13C-NMR and HRMS methods. The cytotoxic properties of the compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method in 3T3 cell line. Among the 15 compounds, the three compounds with the lowest cytotoxic properties were selected for further experiments. Inflammation was induced by lipooxygenase (LPS) and the effects of the selected compounds on the levels of reactive oxygen species (ROS), cytokines, complement C3 and C9 regulatory proteins were investigated. It was found that three selected compounds decreased the transforming growth factor beta 1 (TGF-b1) levels. Among these compounds, compound 3e provided the most significant decrease in this cytokine. Moreover, compound 3e increased both C3 and C9 levels. Molecular modeling studies also showed that compound 3e has a better affinity for TGF-b1. When the binding modes of these compounds in the active site of TGF-b1were analyzed, it was found that compound 3e had hydrophobic interactions with amino acids Leu142, Tyr84, and Ile13; halogen bond interactions with Asp92 and hydrogen bond interactions with amino acids Ser89, Gly88, and Gly14 in the active binding site. Further in vitro and in vivo studies are needed to show the possible mechanism of action of compound 3e.
- Open Access
- 8 February 2024
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 80 (3) , 281-288
Syntheses, characterizations, crystal structures and Hirshfeld surface analyses of methyl 4-[4-(difluoromethoxy)phenyl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, isopropyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate and tert-butyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
The crystal structures and Hirshfeld surface analyses of three similar compounds are reported. Methyl 4-[4-(difluoromethoxy)phenyl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C21H23F2NO4), (I), crystallizes in the monoclinic space group C2/c with Z = 8, while isopropyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C23H27F2NO4), (II) and tert-butyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C24H29F2NO4), (III) crystallize in the orthorhombic space group Pbca with Z = 8. In the crystal structure of (I), molecules are linked by N—H...O and C—H...O interactions, forming a tri-periodic network, while molecules of (II) and (III) are linked by N—H...O, C—H...F and C—H...π interactions, forming layers parallel to (002). The cohesion of the molecular packing is ensured by van der Waals forces between these layers. In (I), the atoms of the 4-difluoromethoxyphenyl group are disordered over two sets of sites in a 0.647 (3): 0.353 (3) ratio. In (III), the atoms of the dimethyl group attached to the cyclohexane ring, and the two carbon atoms of the cyclohexane ring are disordered over two sets of sites in a 0.646 (3):0.354 (3) ratio.
- 8 February 2024
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 80 (3) , 281-288
Open AccessSyntheses, characterizations, crystal structures and Hirshfeld surface analyses of methyl 4-[4-(difluoromethoxy)phenyl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, isopropyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate and tert-butyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
The crystal structures and Hirshfeld surface analyses of three similar compounds are reported. Methyl 4-[4-(difluoromethoxy)phenyl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C21H23F2NO4), (I), crystallizes in the monoclinic space group C2/c with Z = 8, while isopropyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C23H27F2NO4), (II) and tert-butyl 4-[4-(difluoromethoxy)phenyl]-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (C24H29F2NO4), (III) crystallize in the orthorhombic space group Pbca with Z = 8. In the crystal structure of (I), molecules are linked by N—H...O and C—H...O interactions, forming a tri-periodic network, while molecules of (II) and (III) are linked by N—H...O, C—H...F and C—H...π interactions, forming layers parallel to (002). The cohesion of the molecular packing is ensured by van der Waals forces between these layers. In (I), the atoms of the 4-difluoromethoxyphenyl group are disordered over two sets of sites in a 0.647 (3): 0.353 (3) ratio. In (III), the atoms of the dimethyl group attached to the cyclohexane ring, and the two carbon atoms of the cyclohexane ring are disordered over two sets of sites in a 0.646 (3):0.354 (3) ratio.